Related Experiment Video
Updated: May 27, 2026
09:39
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
Published on: February 7, 2021
A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles
Qiang Peng1, Zhi-Rong Zhang, Tao Gong
1Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, PR China.
Biomaterials
|November 25, 2011
Summary
Biodegradable nanoparticles loaded with insulin phospholipid complexes offer sustained insulin release for over 3 days, significantly enhancing bioavailability and patient compliance in diabetes management.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Nanotechnology
Background:
- Hydrophilic drugs like insulin pose challenges for sustained delivery.
- Biodegradable polymers offer potential for controlled drug release applications.
- Phospholipid complexation can improve drug loading and stability.
Purpose of the Study:
- To develop and characterize insulin phospholipid complex loaded biodegradable poly(hydroxybutyrate-co-hydroxyhexanoate) nanoparticles (INS-PLC-NPs).
- To evaluate the in vitro release profile and in vivo hypoglycemic effect of INS-PLC-NPs.
- To assess the pharmacological bioavailability of insulin delivered via INS-PLC-NPs.
Main Methods:
- Preparation of INS-PLC-NPs using a solvent evaporation method.
- Characterization of nanoparticle size, zeta potential, and entrapment efficiency.
- In vitro drug release studies and in vivo hypoglycemic effect assessment in diabetic rats.
Main Results:
- INS-PLC-NPs exhibited a spherical shape with a mean particle size of 186.2 nm and high entrapment efficiency (89.73%).
- In vitro studies showed sustained insulin release (<20% over 31 days) with minimal burst release.
- In vivo studies demonstrated a prolonged hypoglycemic effect (>3 days) and over 350% enhanced pharmacological bioavailability compared to insulin solution.
Conclusions:
- INS-PLC-NPs provide a promising long-lasting insulin delivery formulation, enhancing patient compliance.
- Phospholipid complex loaded biodegradable nanoparticles (PLC-NPs) are effective for sustained delivery of hydrophilic proteins in hydrophobic polymers.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...